Advertisement
UK markets close in 4 hours 8 minutes
  • FTSE 100

    8,441.02
    +59.67 (+0.71%)
     
  • FTSE 250

    20,689.90
    +158.60 (+0.77%)
     
  • AIM

    788.99
    +5.29 (+0.68%)
     
  • GBP/EUR

    1.1625
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2531
    +0.0007 (+0.06%)
     
  • Bitcoin GBP

    50,227.15
    +1,625.66 (+3.34%)
     
  • CMC Crypto 200

    1,303.77
    -54.23 (-3.99%)
     
  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     
  • DOW

    39,387.76
    +331.36 (+0.85%)
     
  • CRUDE OIL

    79.85
    +0.59 (+0.74%)
     
  • GOLD FUTURES

    2,379.90
    +39.60 (+1.69%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,778.79
    +92.19 (+0.49%)
     
  • CAC 40

    8,243.51
    +55.86 (+0.68%)
     

Is Cara Therapeutics a Buy?

Is Cara Therapeutics a Buy?

With the clinical trial process in the rearview mirror, a lot of the risks associated with development are in the past, leaving "only" the risks of competing profitably. Such is the situation of Cara Therapeutics (NASDAQ: CARA), which is developing a drug called Korsuva to treat pruritus. You've probably experienced pruritus (at least to a small degree) before, because it's the sensation of itchiness.